See more : Shinsho Corporation (8075.T) Income Statement Analysis – Financial Results
Complete financial analysis of Aytu BioPharma, Inc. (AYTU) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aytu BioPharma, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Lizhi Inc. (LIZI) Income Statement Analysis – Financial Results
- Earth Life Sciences Inc. (CLTS) Income Statement Analysis – Financial Results
- E.Merge Technology Acquisition Corp. (ETACU) Income Statement Analysis – Financial Results
- Brother Industries, Ltd. (6448.T) Income Statement Analysis – Financial Results
- Totally plc (TLY.L) Income Statement Analysis – Financial Results
Aytu BioPharma, Inc. (AYTU)
About Aytu BioPharma, Inc.
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.00M | 107.40M | 96.67M | 65.63M | 27.63M | 7.32M | 3.66M | 3.22M | 2.56M | 261.78K | 58.93K | 1.75K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Cost of Revenue | 26.42M | 40.77M | 44.39M | 36.43M | 7.55M | 2.20M | 2.05M | 1.42M | 957.08K | 88.11K | 0.00 | -48.25K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 54.59M | 66.63M | 52.28M | 29.20M | 20.08M | 5.12M | 1.61M | 1.80M | 1.61M | 173.67K | 58.93K | 50.00K | 1.75K | 0.00 | 0.00 | 1.75K | 0.00 | 0.00 |
| Gross Profit Ratio | 67.39% | 62.04% | 54.08% | 44.49% | 72.67% | 69.92% | 43.97% | 56.00% | 62.65% | 66.34% | 100.00% | 2,857.14% | 100.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 2.79M | 4.10M | 14.44M | 5.62M | 1.72M | 589.07K | 167.60K | 1.35M | 6.32M | 3.42M | 4.06M | 2.76M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 22.51M | 28.63M | 31.17M | 25.50M | 19.66M | 0.00 | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 0.00 |
| Selling & Marketing | 26.96M | 41.45M | 38.71M | 30.31M | 11.40M | 0.00 | 0.00 | -242.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 49.47M | 70.08M | 69.88M | 55.81M | 34.80M | 19.24M | 17.73M | 17.61M | 8.83M | 4.38M | 2.35M | 47.98K | 58.11K | 129.37K | 54.16K | 54.86K | 54.98K | 46.89K |
| Other Expenses | 7.58M | -4.78M | 4.07M | 6.01M | 4.49M | 2.14M | 6.28M | 1.71M | 664.71K | 4.89K | 6.18K | 6.18K | 7.34K | 4.25K | 2.58K | 2.71K | 0.00 | 0.00 |
| Operating Expenses | 60.57M | 78.96M | 88.39M | 67.44M | 41.01M | 21.96M | 19.45M | 20.66M | 15.81M | 7.81M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Cost & Expenses | 86.26M | 119.73M | 132.77M | 103.87M | 48.57M | 24.17M | 21.50M | 22.08M | 16.77M | 7.89M | 6.41M | 54.16K | 58.11K | 133.62K | 56.74K | 57.57K | 54.98K | 46.89K |
| Interest Income | 0.00 | 9.00K | 14.00K | 6.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.79M | 0.00 | 147.50M | 0.00 | 0.00 | 0.00 | 749.42K | 2.53M | 5.49M | 114.99K | 45.55K | 4.90K | 3.32K | 3.18K | 3.80K | 3.07K | 0.00 | 2.06K |
| Depreciation & Amortization | 8.27M | 8.82M | 10.15M | 7.70M | 4.59M | 2.24M | 1.85M | 1.84M | 874.79K | 118.20K | 97.48K | 4.94K | 6.15K | 6.76K | 9.19K | 8.28K | 7.52K | 6.42K |
| EBITDA | -1.01M | -3.51M | -27.96M | -29.04M | -12.21M | -14.12M | -15.25M | -18.13M | -21.81M | -7.51M | -52.71K | -47.47K | -50.21K | -126.86K | -47.28K | -47.54K | -47.47K | -40.47K |
| EBITDA Ratio | -1.25% | -7.07% | 42.70% | -22.08% | -89.07% | -59.69% | -245.22% | -449.95% | -520.19% | -2,870.37% | -10,604.89% | -2,712.69% | -2,868.91% | 0.00% | 0.00% | -2,716.51% | 0.00% | 0.00% |
| Operating Income | -5.25M | -17.07M | 37.22M | -38.24M | -20.94M | -16.85M | -19.70M | -20.13M | -21.70M | -7.63M | -6.35M | -52.41K | -56.36K | -133.62K | -56.74K | -55.82K | -54.98K | -46.89K |
| Operating Income Ratio | -6.49% | -15.89% | 38.50% | -58.26% | -75.76% | -230.13% | -538.26% | -624.70% | -847.02% | -2,915.53% | -10,770.31% | -2,995.09% | -3,220.34% | 0.00% | 0.00% | -3,189.83% | 0.00% | 0.00% |
| Total Other Income/Expenses | -8.82M | 14.00K | 1.02M | 840.00K | 7.51M | -10.29M | 9.51M | -2.38M | -6.48M | -114.99K | -4.23K | -4.90K | -3.32K | -3.18K | -3.53K | -3.07K | -2.19K | -2.06K |
| Income Before Tax | -14.08M | -17.05M | -110.28M | -58.03M | -13.62M | -27.13M | -10.19M | -22.51M | -28.18M | -7.75M | -6.39M | -57.32K | -59.68K | -136.80K | -56.47K | -58.89K | -48.95K | -48.95K |
| Income Before Tax Ratio | -17.38% | -15.88% | -114.08% | -88.42% | -49.29% | -370.64% | -278.36% | -698.67% | -1,099.73% | -2,959.45% | -10,847.61% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| Income Tax Expense | 1.77M | -57.00K | -110.00K | 259.00K | -9.92M | 20.04M | -2.13M | 1.11M | 8.48M | -23.91K | -813.70K | 911.31K | 3.32K | 3.18K | -548.00 | 3.07K | 2.19K | 2.06K |
| Net Income | -15.84M | -17.05M | -108.78M | -58.29M | -13.62M | -47.17M | -10.19M | -22.51M | -28.18M | -7.72M | -5.58M | -57.32K | -59.68K | -136.80K | -60.27K | -58.89K | -57.17K | -48.95K |
| Net Income Ratio | -19.56% | -15.88% | -113.97% | -88.81% | -13.39% | -644.33% | -278.36% | -698.67% | -1,099.73% | -2,950.32% | -9,466.80% | -3,275.31% | -3,410.00% | 0.00% | 0.00% | -3,365.37% | 0.00% | 0.00% |
| EPS | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| EPS Diluted | -2.86 | -5.11 | -74.01 | -69.60 | -60.20 | -1.21K | -3.06K | -193.19K | -1.29M | -551.67K | -619.85K | -7.16K | -7.46K | -17.10K | -10.05K | -11.78K | -11.43K | -48.95K |
| Weighted Avg Shares Out | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
| Weighted Avg Shares Out (Dil) | 5.54M | 3.34M | 1.47M | 840.00K | 230.00K | 38.97K | 3.33K | 116.51 | 21.77 | 14.00 | 9.00 | 8.00 | 8.00 | 8.00 | 6.00 | 5.00 | 5.00 | 1.00 |
Aytu BioPharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
DENVER, CO / ACCESSWIRE / January 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a fireside chat and host one-on-one...
Aytu BioPharma to Present on the Emerging Growth Conference on December 7, 2023
Webcasted presentation to take place at 1:10pm ET DENVER, CO / ACCESSWIRE / November 30, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that its CEO, Josh Disbrow,...
Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q1 2024 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Robert Blum...
Aytu BioPharma Reports Fiscal 2024 First Quarter Financial Results
Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash balance at September...
Aytu BioPharma Ranked Among Fastest-Growing Companies in North America on Deloitte's Technology Fast 500(TM) for Third Consecutive Year
Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics,...
Aytu BioPharma to Report First Quarter Fiscal 2024 Financial Results on November 14, 2023
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period...
Aytu BioPharma Announces Approval of the Cotempla XR-ODT(R) Manufacturing Site Transfer Prior Approval Supplement
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product Margins DENVER,...
Aytu BioPharma to Present at Lytham Partners Fall 2023 Investor Conference on October 17, 2023
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with...
Best Penny Stocks? 4 Hot Stocks With News This Week
What do you consider the best penny stocks? Are they the ones exploding higher within a single session?
Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript
Aytu BioPharma, Inc. (NASDAQ:AYTU ) Q4 2023 Earnings Call Transcript September 27, 2023 4:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Operator Greetings....
Source: https://incomestatements.info
Category: Stock Reports